Home

John Tilton

CIK 1704251 · Chief Commercial Officer · last filed 2022-10-03

John Tilton is a Chief Commercial Officer who has filed 13 SEC Form 4 insider transactions across 1 company since 2017. The most recent filing shows the insider disposed of $992.3K of BHVN on Oct 3, 2022. Across all open-market trades the lifetime net is −$5.3M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $25.3K across reported positions. 16 SEC filings were submitted jointly with Biohaven Pharmaceutical Holding Co Ltd.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$25.3K

Companies

1

Total Filings

13

Lifetime Open-Market Net

-$5.28M

Filer Profile

Reported Address
C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP
234 CHURCH STREET
NEW HAVEN, CT 06510
Related Filers
Biohaven Pharmaceutical Holding Co Ltd. — 16 joint filings, latest 2022-10-03
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
BHVN Chief Commercial Officer 1,614 $15.69 $25.3K -$5.28M 13 2022-10-03

Recent Filings

13 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2022-10-03 BHVN Disp (D) −6,682 -$992.3K EDGAR
2022-01-07 BHVN Mixed +1,232 -$112.3K EDGAR
2021-11-26 BHVN Mixed +758 -$56.9K EDGAR
2021-01-08 BHVN Mixed +758 -$41.0K EDGAR
2020-11-27 BHVN Mixed +770 -$43.3K EDGAR
2020-06-12 BHVN Mixed — -$3.02M EDGAR
2019-12-20 BHVN Mixed +770 -$25.0K EDGAR
2019-11-27 BHVN Grant (A) — $0 EDGAR
2019-03-14 BHVN Mixed — -$408.2K EDGAR
2019-01-14 BHVN Mixed — -$298.0K EDGAR
Showing 1–10 of 13
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.